RESEARCH ARTICLE

Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson’s Disease Patients

Jose A. Santiago, Judith A. Potashkin*

The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States of America

* judy.potashkin@rosalindfranklin.edu

Abstract

Early diagnosis of Parkinson’s disease (PD) continues to be a major challenge in the field. The lack of a robust biomarker to detect early stage PD patients has considerably slowed the progress toward the development of potential therapeutic agents. We have previously evaluated several RNA biomarkers in whole blood from participants enrolled in two independent clinical studies. In these studies, PD patients were medicated, thus, expression of these biomarkers in de novo patients remains unknown. To this end, we tested ten RNA biomarkers in blood samples from 99 untreated PD patients and 101 HC nested in the cross-sectional Parkinson’s Progression Markers Initiative by quantitative real-time PCR. One biomarker out of ten, COPZ1, trended toward significance (nominal p = 0.009) when adjusting for age, sex, and educational level. Further, COPZ1, EFTUD2 and PTBP1 mRNAs correlated with clinical features in PD patients including the Hoehn and Yahr scale, Movement Disorder Society revision of Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Montreal Cognitive Assessment (MoCA) score. Levels of EFTUD2 and PTBP1 were significantly higher in cognitively normal PD patients (PD-CN) compared to cognitively impaired PD patients (PD-MCI). Interestingly, blood glucose levels were significantly higher in PD and PD-MCI patients (>/=100 mg/dL, pre-diabetes) compared to HC. Collectively, we report the association of three RNA biomarkers, COPZ1, EFTUD2 and PTBP1 with clinical features including cognitive decline in early drug-naive PD patients. Further, our results show that drug-naive PD and PD-MCI patients have glucose levels characteristic of pre-diabetes patients, suggesting that impaired glucose metabolism is an early event in PD. Evaluation of these potential biomarkers in a larger longitudinal study is warranted.

Introduction

Parkinson’s disease (PD) is a debilitating neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Although PD has been largely recognized as a classical movement disorder, non-motor symptoms including...
Blood biomarkers are emerging as promising diagnostic tools for PD. Altered expression of several RNAs [4–8] and microRNAs [9, 10] have been identified in medicated PD patients, although, very few RNA biomarkers have been replicated in samples from independent clinical studies. For instance, a molecular signature in blood composed of 13 splice variants, including CSORF4, COPZ1, MACF1, WLS, PRG3, ZNF160, EFTUD2, MAP4K1, MPP1, PKM2, SLC14A1-s, SLC14A1-l, and ZNF134, was useful to distinguish PD patients from atypical parkinsonian disorders and healthy controls (HC) nested in the Diagnostic and Prognostic Biomarkers for Parkinson’s Disease (PROBE) with 90% sensitivity and 94% specificity [11]. Seven out of the 13 biomarkers including CSORF4, COPZ1, MACF1, WLS, PRG3, ZNF160 and EFTUD2, were replicated in blood of PD patients and HC nested in the Harvard Biomarker Study (HBS) with 78% sensitivity and 90% specificity [12]. Using network-based approaches, other potential RNA biomarkers including APP, SOD2, HNF4A, and PTBP1 were identified as useful for distinguishing PD patients from HC [13–16]. Among this group, HNF4A and PTBP1 were able to distinguish PD patients from HC with 90% sensitivity and 80% specificity.

Despite this progress, PD patients enrolled in all of these studies were already medicated. More recently, one study identified several candidate biomarkers in untreated PD patients, but these have yet to be validated [17]. To test whether markers that have been replicated in independent clinical trials are also useful for diagnosing unmedicated PD patients, we evaluated ten RNA biomarkers in early-stage drug-naïve PD patients and HC enrolled in the Parkinson’s Progression Markers Initiative (PPMI) [18]. We identified three potential blood biomarkers, COPZ1, EFTUD2 and PTBP1, mRNAs that correlated with clinical features in the largest to date cohort of untreated PD patients. Further, EFTUD2 and PTBP1 may be useful to distinguish PD patients with cognitive impairment. Evaluation of these potential biomarkers in a larger longitudinal study and patients at risk of PD is warranted.

Material and Methods

Study Participants

PPMI is an ongoing 5-year observational, longitudinal, and multi-center study of drug-naïve patients with early stage PD (n = 423) and HC (n = 196) recruited from 32 clinical sites in Australia, United States of America (USA) and Europe [18]. A power analysis based on each biomarker from our previous studies [12–15], indicated that a minimum fold change of 1 between PD and controls could be detected with a 95% power using 100 samples per group. Thus, we selected a total of 200 participants, 99 PD patients and 101 age and sex matched HC nested in the PPMI study PD patients that had a dopamine transporter deficit assessed by DaTscan imaging. PD patients with a Hoehn and Yahr stage I or II were chosen for this study so that we could relate the results to our earlier studies on medicated patients at these stages of the disease. Healthy individuals were cognitively normal, free of neurological disorder, and with no detectable dopamine transporter deficit. Among the 99 PD patients, we selected 35 patients with cognitive impairment as defined by a Montreal Cognitive Assessment (MoCA) score of less than 26. Demographic and clinical characteristics about the study participants are shown in Table 1. The Institutional Review Boards of Rosalind Franklin University of Medicine and Science and all sites participating in the PPMI study approved the study. Written informed consent was obtained from all participants before inclusion in the study. All participants were evaluated for constipation, hyposmia, depression, sleep behavior disorders are now being recognized as early prodromal symptoms of the disease [1, 2]. Diagnosis of PD remains challenging and there is a 20–30% misdiagnosis rate with atypical parkinsonian disorders [3]. To date, diagnosis of PD is based on the assessment of clinical motor symptoms. The lack of a robust biomarker with high sensitivity and specificity has greatly hampered the validation of potential therapeutics.
clinical features by investigators at each participant site. More information about study participants have been described elsewhere [19] and at the PPMI website (http://www.ppmi-info.org/).

Blood sample collection and handling
Baseline whole blood collection was performed at each participant site as described in the PPMI biologics manual (http://www.ppmi-info.org/). Blood samples were collected in the morning between 8am-10am, and patients were asked to fast before blood collection. Blood was collected in PAXgene blood RNA tubes following the study protocol. Briefly, PAXgene tubes containing blood were immediately inverted gently 8–10 times to mix the samples. Tubes were placed upright and incubated for 24 hrs at room temperature before freezing. After the 24 hrs incubation period, PAXgene blood tubes were stored at -80°F until shipment. Frozen samples were sent to the PPMI Biorepository Core laboratories for RNA extraction. Blinded frozen samples (n = 200) were shipped in dry ice to Rosalind Franklin University of Medicine for the studies described herein.

Quantitative Polymerase Chain Reaction Assays
Samples with RNA integrity values >7.0 and absorbance 260/280 between 1.2 and 3.0 were used in this study. One microgram of RNA was reverse transcribed into cDNA using a mix of random hexamer primers (High Capacity cDNA Synthesis Kit, Life Technologies, USA). Quantitative polymerase chain reaction assays (qRT-PCR) were performed using the DNA engine Opticon 2 Analyzer (Bio-Rad Life Sciences, Hercules, CA, USA). Each 25 microliters reaction contained Power SYBR Green (Life Technologies, USA) and primers at a

Table 1. Comparison of demographic and clinical characteristics between PD patients and HC.

| Characteristic                              | HC (n = 101)       | PD (n = 99)       | P value a |
|--------------------------------------------|--------------------|------------------|-----------|
| Age, mean (SD) [95% CI], y                 | 61 (10) [59–63]    | 63 (9) [61–65]   | 0.19      |
| Female/male, No. (%male)                   | 45/56 (55.4)       | 49/50 (50.5)     | 0.57 b    |
| Education, mean (SD) [95% CI], y           | 16.2 (2.9) [15.6–16.8] | 15.1 (3.2) [14.4–15.7] | 0.02      |
| Disease duration, months                   | n/a                | 4 (1–36)        | n/a       |
| Hoehn and Yahr stage, mean (SD)            | 0.009 (0.09)       | 1.44 (0.50)     | <0.001    |
| MDS-UPDRS total                           | 4.87 (4.41)        | 31.79 (12.41)   | <0.001    |
| MDS-UPDRS part I                          | 0.60 (1.06)        | 1.28 (1.42)     | <0.001    |
| MDS-UPDRS part I-patient questionnaire     | 2.40 (2.30)        | 4.71 (3.36)     | <0.001    |
| MDS-UPDRS part II-patient questionnaire    | 0.45 (0.99)        | 5.82 (4.13)     | <0.001    |
| MDS-UPDRS part III-patient questionnaire   | 1.43 (2.30)        | 19.98 (8.56)    | <0.001    |
| MoCA, mean (SD) [95% CI]                  | 28.23 (1.07) [28.02–28.44] | 25.98 (2.53) [25.48–26.48] | <0.001    |
| Glucose levels in blood                    | 97.58 (14.13) [94.80–100.4] | 101.6 (14.44) [98.75–104.5] | <0.01    |
| UPSIT score, mean (SD)[95%CI]              | 34.00 (4.86) [33.04–34.96] | 21.08 (8.12) [19.46–22.70] | <0.0001   |
| GDS score, mean (SD) [95% CI]              | 1.27 (1.89) [0.89–1.64] | 2.15 (2.48) [1.64–2.67] | <0.007    |
| SCOPA mean (SD) [95% CI]                   | 5.86 (3.28) [5.21–6.51] | 9.27 (5.40) [8.16–10.38] | <0.0001   |

Demographic and clinical information of PPMI participants. Abbreviations: CI = 95% confidence interval; GDS = Geriatric Depression Scale; HC = healthy controls; MoCA = Montreal Cognitive Assessment; MDS-UPDRS = Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PD = Parkinson’s disease; SCOPA = Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms SD = standard deviation; y = years. UPSIT = University of Pennsylvania Smell Identification Test.

a Based on a Student t-test.

b Based on chi-square test (χ²).
concentration of 0.05 mM. Samples were run in triplicates. Amplification conditions and primer sequences have been published elsewhere [12–15]. All the data collected in this study will be publicly available at (http://www.ppmi-info.org/).

Statistical Analysis

Statistical analysis was performed using STATISTICA 12 (StatSoft, OK, USA) and GraphPad Prism version 5 (GraphPad Software, Inc., CA, USA). A Student-t-test (unpaired, two tailed) was used to assess the differences between two groups and a chi-square test was used to analyze categorical data. Pearson correlation was performed for all correlations. A Pearson correlation analysis of the RIN values and expression of each biomarker showed no significant associations (p = 0.9). The relative abundance of each biomarker was independently assessed using a general linear regression model adjusting for age, sex, and educational level. A Bonferroni adjustment was used to correct for multiple comparisons and a p-value of 0.005 or less was considered significant.

In addition, we evaluated the expression of each RNA biomarker independently in PD patients with cognitive decline compared to cognitively normal PD patients. For this analysis, we used a general linear regression model adjusting for age, gender, education, Hoehn and Yahr, and MDS-UPDRS. A receiver operating characteristic curve (ROC) analysis was performed to determine the diagnostic accuracy of each biomarker. A nominal p-value of 0.05 or less was considered significant.

Results

Demographic characteristics of study participants

There were no significant differences in mean age and sex distribution between PD patients and HC. However, PD patients had a small but significant difference in the number of years they attended school compared to HC (Table 1). As expected, comparisons of clinical features showed significant differences in Hoehn and Yahr stage, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), MoCA score, University of Pennsylvania Smell Identification Test (UPSIT), Geriatric Depression Scale (GDS) and Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA) scores between PD patients and controls (Table 1). We also compared the blood glucose levels in PD patients and controls. Mean blood glucose level was within the normal range in HC (<100 mg/dL) but was significantly higher than normal in the PD group (≥ 100 mg/dL) (Table 1).

Evaluation of RNA biomarkers in blood of PPMI study participants

A total of ten RNA biomarkers were tested in the PPMI cohort by quantitative PCR assays. No significant difference was observed in the expression of 9 of the markers, including EFTUD2, PTBP1, C5ORF4, APP, SOD2, HNF4A, WLS, ZNF160 and MACF1, between PD patients and controls in the univariate analysis (S1 Table). Interestingly however, a small but significant difference in the expression of COPZ1 was identified in the blood of PD patients compared to HC. Specifically, the relative abundance of COPZ1 (p = 0.005) was significantly up-regulated in PD patients compared to HC, although overlap in expression levels between the two groups was observed (Fig 1, S1 Table). In addition, the analysis was performed using a general linear regression model adjusting for confounding variables including age, sex and educational level. Relative abundance of COPZ1 trended toward significance in PD patients compared to HC after adjusting for confounding variables (ß = 0.18, nominal p = 0.009).
Pearson correlation analysis was performed to determine whether the relative abundance of each RNA biomarker was independent of age, gender and educational level and clinical outcome variables. The relative abundance of COPZ1 was independent of age, gender and education (S2 Table). Interestingly, the relative abundance of three biomarkers, COPZ1, EFTUD2 and PTBP1 correlated with measures of disease severity in PD patients. For instance, COPZ1 correlated positively with the Hoehn and Yahr scale, MDS-UPDRS total, and MDS-UPDRS parts II and III. Relative abundance of EFTUD2 correlated negatively with age, Hoehn and Yahr scale, MDS-UPDRS total, MDS-UPDRS parts I, II and III and correlated positively with MoCA (S2 Table). Relative abundance of PTBP1 correlated negatively with MDS-UPDRS parts I and positively with MoCA. In addition, COPZ1 and EFTUD2 correlated negatively with the UPSIT and GDS scores, respectively.

**EFTUD2 and PTBP1 are associated with cognitive decline in PD**

Since cognitive decline is common in PD, we evaluated the clinical differences between cognitively normal PD patients (PD-CN) and PD patients with mild cognitive impairment (PD-MCI). Cognitive impairment was defined using the recommended MoCA cutoff greater than 26 as shown previously [20, 21]. HC were excluded from this analysis. There were no significant differences in age, educational level, disease duration, and disease severity scales including the Hoehn and Yahr and MDS-UPDRS between PD-CN and PD-MCI (Table 2). However, there were a significant higher number of male participants in the PD-MCI group (Table 2). Interestingly, mean blood glucose levels are significantly higher than normal in PD-MCI (mean (SD) 95% CI: 105.8 (15.27) [100.6–111.0]) compared to PD-CN (Table 2).
Given the significant correlation between \textit{EFTUD2} and \textit{PTBP1} with MoCA score we evaluated their capability to distinguish PD-CN from PD-MCI patients. Expression of \textit{EFTUD2} was significantly up-regulated in PD-CN (mean (SD) [95% CI] p-value, 1.21 (0.66) [1.04–1.38] p = 0.04) compared to PD-MCI (0.93 (0.60) [0.72–1.14]) (Fig 2A). In parallel, expression of \textit{PTBP1} was significantly up-regulated in PD-CN (1.30 (0.84) [1.09–1.51] p = 0.02) compared to PD-MCI (0.93 (0.56) [0.73–1.12]) (Fig 2B). Pearson correlation analysis showed that \textit{EFTUD2} expression was independent of age, gender and years of education (\(p > 0.5\)). Similarly, \textit{PTBP1} expression did not correlate with age (\(p = 0.8\)), and gender (\(p = 0.19\)), but it showed a significant but weak correlation with years of education (\(r = -0.20, p = 0.05\)). This analysis was repeated using a general linear regression model adjusting for confounding variables including age, sex, educational level, Hoehn and Yahr, disease duration, and MDS-UPDRS. Both biomarkers, \textit{EFTUD2} (\(\beta = 0.27, p = 0.01\)) and \textit{PTBP1} (\(\beta = 0.22, p = 0.04\)) reached statistical significance. ROC analysis for \textit{EFTUD2} and \textit{PTBP1} resulted in AUC values of 0.64 and 0.63, respectively.

Pearson correlation analysis showed significant and positive correlations among \textit{COPZ1} \textit{EFTUD2} and \textit{PTBP1}. For example, \textit{COPZ1} correlated with \textit{EFTUD2} (\(r = 0.14, p = 0.04\)) and \textit{PTBP1} (\(r = 0.32, p = 0.0001\)). The highest correlation value was observed between \textit{EFTUD2} and \textit{PTBP1} (\(r = 0.61, p = 0.001\)).

\textbf{Discussion}

Validation of candidate biomarkers for PD in several independent clinical studies is an important step toward their effective translation to the clinic. One crucial step in this process is the

\begin{table}
\centering
\small
\begin{tabular}{|c|c|c|c|}
\hline
Characteristic & PD-CN (n = 64) & PD-MCI (n = 35) & P value* \\
\hline
Age, mean (SD) [95% CI], y & 62 (8) [60–64] & 65 (9) [62–68] & 0.17 \\
\hline
Male/Female, No. (%male) & 23/41 (56) & 27/8 (338) & 0.0001b \\
\hline
Education, mean (SD) [95% CI], y & 15.02 (3.44) [14.16–15.87] & 15.14 (2.68) [14.22–16.06] & 0.85 \\
\hline
Disease duration, median (range), months & 4 (1–36) & 5 (1–23) & 0.80 \\
\hline
Hoehn and Yahr stage, mean (SD) & 1.44 (0.50) & 1.46 (0.50) & 0.85 \\
\hline
MDS-UPDRS total & 31.31 (12.34) & 32.66 (12.68) & 0.61 \\
\hline
MDS-UPDRS part I & 1.31 (1.29) & 1.23 (1.64) & 0.78 \\
\hline
MDS-UPDRS part II-patient questionnaire & 4.83 (3.38) & 4.49 (3.35) & 0.63 \\
\hline
MDS-UPDRS part III-patient questionnaire & 6.17 (4.32) & 5.17 (3.73) & 0.25 \\
\hline
MDS-UPDRS part IV-patient questionnaire & 19.00 (7.93) & 21.77 (9.46) & 0.12 \\
\hline
MoCA, mean (SD) [95% CI] & 27.53 (1.08) [27.26–27.80] & 23.14 (1.85) [22.51–23.78] & 0.0001 \\
\hline
UPSIT score, mean (SD) [95% CI] & 21.97 (8.00) [19.97–23.97] & 19.46 (8.18) [16.65–22.27] & 0.14 \\
\hline
GDS score, mean (SD) [95% CI] & 2.00 (2.24) [1.42–2.59] & 2.42 (2.87) [1.41–3.44] & 0.43 \\
\hline
SCOPA, mean (SD) [95% CI] & 9.46 (5.60) [8.02–10.91] & 8.91 (5.08) [7.11–10.71] & 0.64 \\
\hline
Blood glucose levels, mean (SD) [95% CI] & 99.34 (13.55) [95.96–102.7] & 105.8 (15.27) [100.6–111.0] & 0.03 \\
\hline
\end{tabular}
\caption{Comparison of demographic and clinical characteristics of cognitively normal PD patients (PD-CN) and cognitively impaired PD patients (PD-MCI).}
\label{table:comparison}
\end{table}

Demographic and clinical characteristics of cognitively normal PD patients (PD-CN) and cognitively impaired PD patients (PD-MCI). Abbreviations: CI = 95% confidence interval; GDS = Geriatric Depression Scale; HC = healthy controls; MoCA = Montreal Cognitive Assessment; MDS-UPDRS = Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PD = Parkinson’s disease; SCOPA = Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms SD = standard deviation; y = years. UPSIT = University of Pennsylvania Smell Identification Test.
*a Based on Student t-test.
*b Based on chi-square test (X²).

doi:10.1371/journal.pone.0142582.t002
evaluation of biomarkers in drug-naïve patients to ensure that commonly prescribed medications for PD do not have an effect in their expression. Here we tested ten blood RNA biomarkers that were evaluated previously in two independent clinical studies, in blood of untreated PD patients and controls enrolled in the PPMI study.

Three candidate blood biomarkers, \textit{COPZ1}, \textit{EFTUD2} and \textit{PTBP1}, correlated with clinical features in early stage drug-naïve PD patients suggesting they may be useful for patient stratification according to disease severity measures. Specifically, \textit{COPZ1} significantly correlated with Hoehn and Yahr scale, MDS-UPDRS total, MDS-UPDRS parts II and III and UPSIT score. Similarly, \textit{EFTUD2} showed significant correlations with Hoehn and Yahr, MDS-UPDRS total, MDS-UPDRS parts I, II, and III, MoCA and GDS scores. In addition, \textit{PTBP1} significantly correlated with MDS-UPDRS part I, and MoCA score. These findings suggest that \textit{COPZ1}, \textit{EFTUD2} and \textit{PTBP1} may be useful biomarkers to classify PD patients with regards to symptoms. Nonetheless, these results need to be taken with caution since the biomarker correlations with clinical features were relatively weak. Thus, evaluation of these potential biomarkers in a larger longitudinal study will be required to assess their prognostic utility.

One biomarker, \textit{COPZ1} trended toward significance (nominal $p = 0.009$) after adjusting for age, sex and educational level. It is important to note, that we observed overlap in the relative abundance of \textit{COPZ1} between PD and controls and low diagnostic capacity. In addition, we previously reported that the relative abundance of \textit{COPZ1} was up-regulated in blood of medicated PD patients enrolled in two independent clinical studies [11, 12]. It should be noted that the magnitude of the change in \textit{COPZ1} expression was greater in our earlier reports using medicated PD patients compared to unmedicated patients in this report (5-fold vs 1.5-fold). Together these results suggest that medication has an impact on the expression of \textit{COPZ1}.

Cognitive decline is a common non-motor aspect of PD that frequently progresses to dementia. In fact, up to 80% of PD patients with mild cognitive impairment will eventually develop dementia [22]. Thus, biomarkers that predict changes in cognitive abilities are essential for the development of therapeutic strategies for PD [23]. Several potential biomarkers of cognitive decline have been identified. For example, CSF levels of amyloid beta peptides (Aβ), but
not total tau, were associated with cognitive impairment in untreated PD patients enrolled in the Norwegian ParkWest study [24]. Contrary to these findings, Aβ peptides, total tau and phosphorylated tau (p-tau) did not correlate with cognitive measures in untreated patients in a larger cohort of patients enrolled in Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study. However, higher p-tau and p-tau/Aβ42 levels in the CSF predicted cognitive decline in PD patients after levodopa treatment [25]. In addition, serum levels of the insulin growth factor 1 (IGF-1) and epidermal growth factor (EGF) are associated with cognitive decline in early stage and drug-naive patients with PD [26–30]. Approximately 10% of PD patients met the criteria for cognitive impairment in the PPMI study [21]. In this study, relative abundance of EFTUD2 and PTBP1 was significantly up-regulated in PD-CN compared to PD-MCI independently of age, gender, disease duration, and disease severity measures. To the best of our knowledge, these are the first blood RNA biomarkers that have been associated with cognitive decline in PD. Future studies in larger and well-characterized longitudinal studies will be important to assess their predictive performance in PD patients.

The biomarkers examined in this study are related to biological processes associated with PD. For example, COPZ1 encodes a subunit of the cytoplasmic coatamer complex, which is involved in autophagy and protein trafficking. EFTUD2, elongation factor Tu GTP binding domain containing 2, which encodes the splicing factor U5-116 kD, is involved in RNA splicing via the spliceosome. In this regard, the involvement of aberrant RNA splicing in blood of PD has been noted in numerous studies [7, 11, 12, 15], reviewed in [31]. In this regard, a recent study identified a network of dysregulated splicing factors in blood of PD patients supporting the idea that splicing may be both inefficient and dysregulated in PD [15].

The polyprimidine tract binding protein1 (PTBP1) belongs to the family of heterogeneous nuclear ribonucleoproteins (hnRNPs) that are involved in pre-mRNA processing, metabolism and transport. PTBP1 plays a pivotal role in the mRNA stabilization and translation of insulin in the pancreas and it has been associated with diabetes [32]. Thus, altered expression of PTBP1 may be an important indicator of impaired glucose and insulin signaling in de novo PD patients.

In this context, mounting evidence indicates that impaired glucose metabolism, insulin signaling and diabetes are associated with PD [13, 33, 34]. Treatment with levodopa exacerbates glucose intolerance in PD patients [35, 36], but abnormal blood glucose levels in untreated PD patients have not yet been reported. According to the American Diabetes Association (http://www.diabetes.org/diabetes-basics/diagnosis/), fasting blood glucose levels ≥100 mg/dL are characteristic of subjects with pre-diabetes. Accordingly, blood glucose levels were significantly higher than normal in PD (101.6 mg/dL) and PD-MCI (105.8 mg/dL) patients. Thus, we report for the first time that drug-naive PD and PD-MCI patients have glucose levels characteristic of pre-diabetes patients, suggesting that impaired glucose metabolism is an early event in PD. These results are representative of a subset of participants enrolled in PPMI study and therefore warrant further investigation.

Collectively, we report the association of three RNA biomarkers with clinical features including cognitive decline in early drug-naive PD patients. Nevertheless, the diagnostic performance of these biomarkers is low and below the ideal characteristics for a diagnostic biomarker. There are several important factors that need to be considered when interpreting the results from this study and its discrepancies from our previous studies. First, our biomarkers were tested previously in very homogenous clinical studies in the USA [11, 12, 14, 15], where most of the PD patients were medicated. PPMI is an international multicenter study of drug-naive PD patients and HC recruited from 32 different clinical sites including Europe, Australia and USA. Thus, other factors related to the diverse ethnic backgrounds, diet, and epigenetic changes, for example, may explain the discrepancies in biomarker expression observed in this
study. In addition, even with the rigorous standard procedures for sample collection, processing and storage followed by the PPMI study, there is a potential for pre-analytical variability introduced by the different clinical sites [37].

Unbiased approaches are needed to identify highly sensitive and specific diagnostic biomarkers for the identification of early stage and pre-symptomatic PD patients [38]. We foresee that emerging high-throughput technologies combined with network analyses using early stage untreated and/or pre-symptomatic PD patients will be instrumental in the discovery of new potential biomarkers [16]. Evaluation of these biomarkers in larger longitudinal studies is needed to test further their prognostic and diagnostic utility.

Supporting Information

S1 Table. Relative expression levels of blood biomarkers in HC and patients with PD. *Assessed by Student t-test (two-tailed). CI is the 95% confidence interval. A p-value of 0.005 or less was considered significant. (DOC)

S2 Table. Pearson (r) correlation of blood biomarkers with clinical outcomes. Pearson correlation (r) is shown for each of the biomarkers and the clinical outcome variables. P-values for significant correlations are shown in parenthesis. Abbreviations: GDS = Geriatric Depression Scale; HC = healthy controls; MoCA = Montreal Cognitive Assessment; MDS-UPDRS = Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PD = Parkinson’s disease; SCOPA = Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms; y = years. UPSIT = University of Pennsylvania Smell Identification Test (DOC)

Acknowledgments

Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, GE healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, and UCB found at www.ppmi-info.org/fundingpartners.

Author Contributions

Conceived and designed the experiments: JAS JAP. Performed the experiments: JAS. Analyzed the data: JAS JAP. Wrote the paper: JAS JAP.

References

1. Martinez-Martín P, Chaudhuri KR, Rojo-Abuin JM, Rodríguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015; 22(1):37–43. Epub 2013/04/24. doi: 10.1111/ene.12165 PMID: 23607783.

2. Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AH, Brown RG, et al. The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord. 2015; 21(3):287–91. Epub 2015/01/27. doi: 10.1016/j.parkreldis.2014.12.031 PMID: 25616694.

3. Rajput AH, Rajput A. Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology. 2014; 83(5):386–7. Epub 2014/07/01. doi: 10.1212/WNL.0000000000000653 PMID: 24975658.
Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson disease. Diagnostics. 2014; 4(4):153–64. doi: 10.3390/diagnostics4040153

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007; 104(3):955–60. Epub 2007/01/12. doi: 10.1073/pnas.0610204104 PMID: 17215369; PubMed Central PMCID: PMC1766335.

Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener. 2012; 7:26. Epub 2012/06/02. doi: 10.1186/1750-136X-7-26 PMID: 22651796; PubMed Central PMCID: PMC3424147.

Alieva A, Shadrina Mi, Filatova EV, Karabanov AV, Illarioshkin SN, Limborska SA, et al. Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson's disease. BioMed Res Int. 2014; 2014:718732. Epub 2014/05/08. doi: 10.1155/2014/718732 PMID: 24048238; PubMed Central PMCID: PMC3996366.

Karlsson MK, Sharma P, Aasly J, Toft M, Skogar O, Saebø S, et al. Found in transcription: accurate Parkinson's disease classification in peripheral blood. J Parkinsons Dis. 2013; 3(1):19–29. Epub 2013/08/14. doi: 10.3233/JPD-120159 PMID: 23938308.

Serafin A, Foco L, Zanigni S, Blankenburg H, Picard A, Zanon A, et al. Overexpression of blood micro-RNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. Neurology. 2015; 84(7):645–53. Epub 2015/01/18. doi: 10.1212/00000000000001258 PMID: 25596505.

Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, et al. Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PLoS One. 2011; 6(10):e25443. Epub 2011/10/18. doi: 10.1371/journal.pone.0025443 PMID: 22003392; PubMed Central PMCID: PMC3189215.

Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA. Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients. PLoS One. 2012; 7(8):e43595. Epub 2012/09/07. doi: 10.1371/journal.pone.0043595 PMID: 22952715; PubMed Central PMCID: PMC3428307.

Santiago JA, Scherzer CR, Potashkin JA. Specific splice variants are associated with Parkinson's disease. Mov Disord. 2013; 28(12):1724–7. Epub 2013/10/11. doi: 10.1002/mds.25635 PMID: 24108702; PubMed Central PMCID: PMC3812386.

Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS One. 2013; 8(12):e83940. Epub 2014/01/01. doi: 10.1371/journal.pone.0083940 PMID: 24376773; PubMed Central PMCID: PMC3869818.

Santiago JA, Scherzer CR, Potashkin JA. Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS One. 2014; 9(10):e109042. Epub 2014/10/04. doi: 10.1371/journal.pone.0109042 PMID: 25279756; PubMed Central PMCID: PMC4184821.

Santiago JA, Potashkin JA. Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease. Proc Natl Acad Sci U S A. 2015; 112(7):2257–62. Epub 2015/02/04. doi: 10.1073/pnas.1423573112 PMID: 25646437.

Santiago JA, Potashkin JA. A network approach to clinical intervention in neurodegenerative diseases. Trends Mol Med. 2014; 20(12):694–703. Epub 2014/12/03. doi: 10.1016/j.molmed.2014.10.002 PMID: 25450503.

Infante J, Prieto C, Sierra M, Sanchez-Juan P, Gonzalez-Aramburu I, Sanchez-Quintana C, et al. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2:G2019S carriers, idiopathic cases, and controls. Neurobiol Aging. 2015; 36(2):1105–12. Epub 2014/12/06. doi: 10.1016/j.neurobiolaging.2014.10.039 PMID: 25475535.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Cappelli C, Coffey CS, et al. Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013; 70(10):1277–87. Epub 2013/08/28. doi: 10.1001/jamaneurol.2013.3861 PMID: 23979011; PubMed Central PMCID: PMC4034348.

The Parkinson Progression Marker Initiative (PPMI), Prog Neurobiol. 2011; 95(4):629–35. Epub 2011/09/21. doi: 10.1016/j.pneurobio.2011.09.005 PMID: 21930184.

Dalymply-Allford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010; 75(19):1717–25. Epub 2010/11/10. doi: 10.1212/WNL.0b013e3181fc29c9 PMID: 21050094.

Weintraub D, Simuni T, Cappelli-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015. Epub 2015/03/05. doi: 10.1002/mds.26170 PMID: 25737166.

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60(3):387–92. Epub 2003/03/14. PMID: 12633150.
23. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord. 2014; 29(5):622–33. Epub 2014/04/24. doi: 10.1002/mds.25846 PMID: 24757111; PubMed Central PMCID: PMC4384332.

24. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080–6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 PMID: 20547614.

25. Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080–6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 PMID: 20547614.

26. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080–6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 PMID: 20547614.

27. Liao C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080–6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 PMID: 20547614.

28. Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080–6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 PMID: 20547614.

29. Liao C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080–6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 PMID: 20547614.